Chris Hurt

Biography

Education and qualifications

2018: PgD Autism and Related Conditions (with Distinction), Swansea

2004: MSc Applied Statistics (with Distinction), Sheffield

1998: MSc Computing Science (with Merit), Birkbeck College, London

1994: BSc Ecology (2i), University of Sheffield

Honours and awards

Honorary Member of the Royal College of Radiologists: 2015 to present

Academic positions

2007- present: Senior Statistician, Cardiff University

2006-7: Principal Researcher, Office for National Statistics (Civil Service Fast Stream)

2004-6: Statistician, London School of Hygiene and Tropical Medicine

2001-4: Research Fellow, Advanced Computation Laboratory, Cancer Research UK

2000-2001: Statistical Programmer, Imperial College London

1999-2000: Analyst Programmer, University of Oxford

Committees and reviewing

Member of the Cancer Research UK Clinical Expert Review Panel: 2011-present

Member of the NCRI Clinical and Translational Radiotherapy Research Working Group: 2009 -present

Member of the Public Health Wales Bowel Screening Research Group: 2015-present

Member of the Southampton Clinical Trials Unit Trial Steering Committee: 2020-present

Statistical Editor for the International Journal of Radiation Oncology, Biology, Physics: 2021-present

Reviewer for the National Institute for Health Research Health Technology Assessment Programme: https://www.nihr.ac.uk/documents/hta-programme-reviewers-list/20813#E-H

Chair of the Independent Monitoring Committee for the following national and international trials:

• ARISTOTLE - A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer
• HYBRID - A multicentre randomised phase II study of HYpofractionated Bladder Radiotherapy with or without Image guided aDaptive planning
• RAIDER - A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder
• NEPTUNES - Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature

Member of the Independent Monitoring Committee for the following national and international trials:

• ART-DECO - A Randomised Multicentre Accelerated Radiotherapy Study of Dose Escalated Intensity Modulated Radiotherapy vs Standard Dose Intensity Modulated Radiotherapy in Patients Receiving Treatment for Locally Advanced Laryngeal and Hypopharyngeal Cancers
• COSTAR - A Multicentre Randomised Study Of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy In Patients With Parotid Tumours
• DARS – A phase III randomised multicentre study of dysphagia optimised intensity modulated radiotherapy (Do-IMRT) versus standard intensity modulated radiotherapy (S-IMRT) in head and neck cancer.
• E-PREDICT - A Phase I Study Of Everolimus Therapy Before Nephrectomy In Metastatic Renal Cell Cancer.
• REALISTIC - A Phase I, Dose Escalation Trial Of Recombinant Listeria Monocytogenes (Lm)-Based Vaccine Encoding Human Papilloma Virus Serotype 16 Target Antigens (ADXS11-001) In Patients With HPV-16 +ve Oropharyngeal Carcinoma.
• ABC-07 - Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers.
• LITEFORM - A Randomised Controlled Trial of the Clinical and Cost Effectiveness of Low Level Laser in the Management of Oral Mucositis in Head and Neck Cancer Irradiation.

Publications

We are currently unable to retrieve the list of publications. Visit our institutional repository.

Teaching

Co-supervisor for research projects on the Intercalated BSc in Population Medicine at Cardiff University

2007-present: Module Organiser (Statistics for Epidemiology) on the MSc Epidemiology at the London School of Hygiene and Tropical Medicine

2011-2014: Member of the exam board for Fellowship of the Royal College of Radiologists (FRCR)

2009-2011: Lecturer (Study Design) on the MSc Palliative care at Cardiff University

I am interested in designing studies and analysing data to improve health outcomes.

Currently I am a co-investigator on the following funded projects and programme grants:

VALTIVE1: Validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors: Optimising the design of a subsequent randomised discontinuation trial (CRUK; £1.00 million; 2010-2024)

CONSCOP2: Randomised controlled trial of contrast enhanced colonoscopy in the reduction of right sided bowel cancer (NIHR HTA; £2.20 million; 2019-2025)

Trials unit core funding: Cancer Division of the Centre for Trials Research (NIHR HTA; £5.50 million; 2018-2023)

PATHOS Phase III: Post-operative adjuvant treatment for HPV-positive tumours Phase 3 (CRUK; £2.10 million; 2018-2027)

Best-of: Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0 oropharyngeal carcinoma (CRUK; £0.32 million; 2017-2025)

SCOPE2: A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET) (CRUK; £1.68 million; 2015-2024)

Supervision

I am interested in supervising PhD students in the areas of:

• methodology involved in the design and analysis of oncology trials
• colorectal cancer screening
• radiation oncology

Past projects

Co-supervisor intercalated BSc project: “Impact of the bowel cancer screening programme on mortality from colorectal cancer in Wales” (2020)

Co-supervisor for Emma Higgins MD: "Development of multivariable normal tissue complication probability (NTCP) models for swallowing dysfunction after curative radiotherapy/chemo-radiotherapy in HPV positive oropharyngeal squamous cell cancer" (2020)

Co-supervisor MSc Palliative Care project: “Quality of life in palliative care centres” (awarded 2011)